Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Related Posts
Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]
Chao ES, Yoshikawa G, Qing X, Huang C. Hyperferritinemia as a Clue to Neuroendocrine Carcinoma. Cureus. 2025 Aug 13;17(8):e90020. doi: 10.7759/cureus.90020. PMID: 40951183; PMCID: PMC12431798.
Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]